BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...
Hindenburg Research founder Nate Anderson, a foe of Carl Icahn and the Adani family, cites the stress of his job as he shuts down the firm.
Gov. Newsom committed California to making its own insulin. It’s at least a year behind his schedule
Gov. Newsom in 2020 signed a law allowing California to manufacture its own insulin, an effort to bring down the cost of the ...
Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Today is like a little taste of what the year could be like if everything goes just right. Inflation is cooler, bond yields ...
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...
Cool wholesale inflation numbers provide only slight relief before Wednesday's release of December Consumer Price Index data.
1d
Most U.S. stocks rose Jan. 14 following an encouraging update on inflation, but drops for pharmaceutical giant Eli Lilly and ...
Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback